41 studies found for:    Open Studies | "Acromegaly"
Show Display Options
Rank Status Study
21 Recruiting Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment
Conditions: Acromegaly;   Excessive Growth Hormone Secretion;   Insulin Resistance
Intervention: Procedure: Transsphenoidal adenomectomy
22 Recruiting Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
Condition: Acromegaly
Intervention:
23 Unknown  Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly
Condition: Acromegaly
Intervention:
24 Recruiting Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly
Condition: Acromegaly
Interventions: Other: 1H/31P Magnetic Resonance Spectroscopy;   Other: oral glucose tolerance testing;   Other: Thyroid sonography
25 Recruiting Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Condition: Acromegaly
Interventions: Drug: Lanreotide Autogel®;   Drug: Lanreotide Acetate
26 Recruiting Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Condition: Acromegaly
Intervention: Drug: Lanreotide PRF
27 Recruiting Acromegaly Combination Treatment Study
Condition: Acromegaly
Interventions: Drug: Pegvisomant;   Drug: Somatostatin Receptor Ligand (SRL)
28 Unknown  Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
Condition: Acromegaly
Intervention:
29 Unknown  Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
Conditions: Acromegaly;   Type 2 Diabetes Mellitus
Interventions: Other: oral glucose tolerance test;   Other: Subcutaneous administration of recombinant human IGF-1
30 Recruiting Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
Condition: Acromegaly
Intervention: Drug: Sandostatin (Octreotide Acetate)
31 Recruiting Phase II Study With ITF2984 in Acromegalic Patients
Condition: Active Acromegaly
Interventions: Drug: Octreotide;   Drug: ITF2984 500 mcg;   Drug: ITF2984 1000 mcg;   Drug: ITF2984 2000 mcg
32 Recruiting Acromegaly Treatment Quality of Life Study
Condition: Acromegaly
Intervention:
33 Recruiting Predictive Factors Study
Condition: Acromegaly
Intervention: Drug: Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
34 Unknown  Estrogen Treatment in Acromegalic Women
Condition: Acromegaly
Intervention: Drug: Alesse
35 Recruiting Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Conditions: Acromegaly;   Gigantism;   Familial Isolated Pituitary Adenoma;   FIPA;   Pituitary Adenoma Predisposition;   PAP
Intervention:
36 Recruiting A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Condition: Acromegaly
Intervention: Drug: lanreotide
37 Unknown  Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs
Condition: Acromegaly
Intervention: Other: Oral Glucose Tolerance Test (OGTT)
38 Recruiting The Observational Study of Growth Hormone-secreting Pituitary Tumors
Conditions: Acromegaly;   Pituitary Tumor
Intervention:
39 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
40 Recruiting Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Condition: Pituitary Tumours
Intervention: Procedure: Gallium-68 DOTATOC PET

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-41) Show next page of results    Last Page
Indicates status has not been verified in more than two years